Absci Sees Strong Gains Amid Mixed Market Activity
Absci (ABSI), the Vancouver‑based synthetic‑biology firm, experienced a notable surge in its share price during a 24‑hour trading window that concluded at 12:27 PM Central Europe on Thursday, 22 March 2026. The stock rose by 10.69 %, trading at approximately USD 10.04 on major exchanges.
With a current supply of 172 million shares and a market capitalization of USD 1.6 billion, the company has attracted considerable investor attention. In the last 24 hours, roughly USD 53.7 million of Absci stock changed hands. Despite this recent upside, the stock has been down 6.26 % since the end of the previous month, reflecting broader market volatility.
Technical Landscape
Absci’s 200‑day simple moving average sits at USD 6.24, indicating a long‑term trend that has been steadily upward. The share’s 52‑week high—reached on 29 June 2026—stood at USD 12.06, while its 52‑week low, recorded on 12 March 2026, fell to USD 2.24. These figures illustrate the company’s capacity to rebound from recent lows and reach new highs.
Comparative Performance
The performance of Absci’s peers over the same 24‑hour period offers additional context:
| Stock | Change | Current Price | Market Cap |
|---|---|---|---|
| Septerna (SEPN) | +3.58 % | USD 40.76 | USD 1.8 bn |
| Maravai Lifesciences (MRVI) | +5.14 % | USD 7.57 | USD 1.9 bn |
| Zenas Biopharma (ZBIO) | –0.35 % | USD 28.08 | USD 1.8 bn |
| Xencor (XNCR) | +0.88 % | USD 25.16 | USD 1.9 bn |
| Establishment Labs (ESTA) | +1.98 % | USD 62.28 | USD 1.9 bn |
While most of these companies enjoyed modest gains, Absci’s stronger performance suggests a particular confidence among investors in its strategic direction.
Company Profile
Absci Corporation, headquartered in Vancouver, Canada, positions itself at the intersection of synthetic biology and healthcare. Its mission is to revolutionize biologic drug discovery and development by bridging theoretical insights with practical applications. The firm offers an integrated platform that aims to become a one‑stop solution for clients across the United States, streamlining the journey from conceptualization to commercialization.
Investors and stakeholders interested in exploring Absci’s portfolio and recent breakthroughs can visit the company’s website at www.absci.com . As a Nasdaq‑listed entity, Absci continues to attract attention from both institutional and retail investors seeking exposure to cutting‑edge biotechnological innovations.
